Jonathan Campbell | Chief Science Officer
National Pharmaceutical Council

Jonathan Campbell, Chief Science Officer, National Pharmaceutical Council

Jonathan D. (Jon ) Campbell, PhD, is the Chief Science Officer (CSO) of the National Pharmacerutical Council (NPC), which sponsors and conducts research on health policy issues related to the development and use of innovative biopharmaceuticals to improve the health of patients. As CSO, Dr. Campbell leads NPC's research agenda in consert with NPC's board and research team.  As a research and advocate for improving the U.S. healthcare system through sustainable access and biopharmaceutical innovation, Dr. Campbell is dedicated to conducting research that helps decision-makers understand the tradeoffs and consequences of health policies that impact patient access to treatments and the ecosystem of biopharmaceutical innovation. Dr. Campbell shaped his career within academics.  After training at the University of Washington, he joined the faculty at the University of Colorao Anschutz Medical Campus, earning multiple appointments in Pharmacy and Public Health from 2009-2020.  During his academic career, Dr. Campbell gained insights on the work of biopharmaceutical manufacturers through a summer internship at Novartis in Basel, Switzerland (2004) and expanded his research and training network through a sabbatical in Budapest, Hungary with Syreon Research Institute (2018). Prior to joining NPC, Dr. Campbell served as Senior Vice President for Health Economics at the Institute for Clinical and Economic Review (ICER), where he made contributions to ICER assessments and their value assessment methodology.  Dr. Campbell is an author of over 250 manuscripts and abstracts and holds an adjunct faculty appointment within the Center for Evaluation of Value and Risk in Health at Tufts University School of Medicine. Dr. Campbell's training includes graduate degrees in pharmaceutical outcomes research (PhD) and biostatistics (MS) from the University of Washington.  He graduated Phi Beta Kappa with Bachelor of Arts degrees in mathematics and chemistry from St. Olaf College.    

Appearances:



Day 1 - Tuesday 28 October @ 14:55

Panel: Challenge of Demonstrating Clinical Meaningfulness in the Context of Rare Disease

Session led by: Biogen
last published: 25/Oct/25 16:45 GMT

back to speakers

Get involved at World Orphan Drug Congress Europe 2025

 

 

TO SPONSOR


Steph Scanlon

Steph.Scanlon@terrapinn.com

 

TO SPEAK


Abdu Kauroo
Abdu.Kauroo@terrapinn.com

 

MARKETING & PRESS


Jasper Cameron

Jasper.Cameron@terrapinn.com

 

Stay Up-to-Date

Join our mailing list to receive exclusive content and offers.

By submitting, you agree to receive email communications from Terrapinn, including upcoming promotions and discounted tickets and news.